Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment

  title={Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment},
  author={Kathleen M. Daddario-DiCaprio and Thomas W. Geisbert and Ute Str{\"o}her and Joan B. Geisbert and Allen Grolla and Elizabeth A. Fritz and Lisa Fernando and Elliott Kagan and Peter B. Jahrling and Lisa E Hensley and Steven J M Jones and Heinz Feldmann},
  journal={The Lancet},

Figures and Tables from this paper

Durability of a Vesicular Stomatitis Virus-Based Marburg Virus Vaccine in Nonhuman Primates
These data are the first to show 100% protective efficacy against any high dose filov virus challenge beyond 8 weeks after final vaccination, demonstrating the durability of VSV-based filovirus vaccines.
A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge
A rVSV vector expressing MARV glycoprotein (rVSV-N4CT1-MARV-GP) fully protected nonhuman primates from lethality and disease when given as soon as 1 week prior to exposure, highlighting the utility of Vesiculovax vaccines for MVD outbreak management.
A Cloned Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine, PHV01, Protects Guinea Pigs from Lethal Marburg Virus Disease
A guinea pig model is used to confirm the protective efficacy of a cloned, rVSV-based candidate vaccine, termed PHV01, expressing the MARV variant Angola glycoprotein, and identifiesPHV01 as a suitable vaccine candidate for advanced development.
Immune correlates of postexposure vaccine protection against Marburg virus
Results suggest dysregulated immunoregulation is associated with poor prognosis, whereas early innate signaling and Th1-skewed immunity are important for survival, as well as novel correlates of postexposure protection.
Cross-Protection against Marburg Virus Strains by Using a Live, Attenuated Recombinant Vaccine
Protection against two heterologous MARV strains, the seemingly more pathogenic Angola strain and the more distantly related Ravn strain is evaluated, suggesting that the VSVΔG/MARVGP-Musoke vaccine should be sufficient to protect against all knownMARV strains.
Single Dose of a VSV-Based Vaccine Rapidly Protects Macaques From Marburg Virus Disease
The data demonstrate that the VSV-MARV is a fast-acting vaccine suitable for the use in emergency situations like disease outbreaks in Africa.
Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates
Abstract A recombinant vesicular stomatitis virus (rVSV) expressing the Marburg virus (MARV) Musoke variant glycoprotein fully protects macaques against 2 MARV variants and Ravn virus as a preventive
Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever.
The data suggest that the Ebola virus vaccine is highly potent and safe and that it very rapidly induces "sterile" immunity in mice, which makes it an excellent candidate for mass immunization during outbreaks or in the event of intentional release.
Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.
A single injection of blended rVSV-based filovirus vaccines was shown to completely protect nonhuman primates against Marburg virus and 3 different species of Ebola virus.


Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
The data suggest that these replication-competent vaccines against EBOV and MARV based on attenuated recombinant vesicular stomatitis virus vectors are safe and highly efficacious in a relevant animal model.
Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.
An RNA replicon, based upon Venezuelan equine encephalitis (VEE) virus, was used as a vaccine vector; the VEE structural genes were replaced by genes for MBGV GP, nucleoprotein (NP), VP40, VP35, VP30, or VP24.
Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections.
Effective treatment of Ebola infections may require a combination of drugs that inhibit viral replication in monocyte/macrophage-like cells while reversing the pathologic effects (e.g., coagulopathy) consequent to this replication.
Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses
The data suggest that the recombinant VSV can be used to study the role of the viral glycoproteins in virus replication, immune response, and pathogenesis and none of the rVSVs displayed pathogenic potential in animals.
Replication-Competent or Attenuated, Nonpropagating Vesicular Stomatitis Viruses Expressing Respiratory Syncytial Virus (RSV) Antigens Protect Mice against RSV Challenge
It is shown that intranasal vaccination of mice with nondefective VSV recombinants expressing RSV G or RSV F (VSV-RSV F) elicited RSV-specific antibodies in serum as well as neutralizing antibodies to RSV and afford complete protection against RSV challenge and the attenuated, nonpropagating VSVΔG-RSv F is a particularly attractive candidate for a live attenuated recombinant RSV vaccine.
Rabies re-examined.
The Use of Interferon for Emergency Prophylaxis of Marburg Hemorrhagic Fever in Monkeys
Recombinant interferon-α2administered according to the emergency prophylaxis schedule prolonged the mean life-span of monkeys injected with Marburg virus in doses of 100 and 1000 LD50 by 1.9 and 6.1 days, respectively.
Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo
In vivo protection byMonoclonal antibodies reactive with the glycoprotein of vesicular stomatitis virus (VSV) serotypes Indiana and New Jersey were used to protect mice against lethal infection and it was shown that as early as 2 h after infection, neither neutralizing nor nonneutralizing MAb could protect.